Page 153 - 2018_10-Haematologica-web

Upper GI acute GvHD adds minimal prognostic value
with acute graft-versus-host disease of the upper digestive tract. J Gastroenterol Hepatol. 2014;29(11):1867-1872.
6. Xu C-F, Zhu L-X, Xu X-M, Chen W-C, Wu D-P. Endoscopic diagnosis of gastrointesti- nal graft-versus-host disease. World J Gastroenterol. 2008;14(14):2262-2267.
7. Washington K, Jagasia M. Pathology of graft-versus-host disease in the gastrointesti- nal tract. Hum Pathol. 2009;40(7):909-917.
8. Parfitt JR, Jayakumar S, Driman DK. Mycophenolate mofetil-related gastroin- testinal mucosal injury: variable injury pat- terns, including graft-versus-host disease- like changes. Am J Surg Pathol. 2008; 32(9):1367-1372.
9. Washington K, Bentley RC, Green A, et al. Gastric graft-versus-host disease: a blinded histologic study. Am J Surg Pathol. 1997; 21(9):1037-1046.
10. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
11. Rowlings PA, Przepiorka D, Klein JP, et al. BMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol. 1997;97(4):855-864.
12. Martino R, Romero P, Subira M, et al. Comparison of the classic Glucksberg crite- ria and the IBMTR Severity Index for grad- ing acute graft-versus-host disease follow- ing HLA-identical sibling stem cell trans- plantation. International Bone Marrow Transplant Registry. Bone Marrow Transplant. 1999;24(3):283-287.
13. Mielcarek M, Furlong T, O’Donnell PV, et al. Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation. Blood. 2016;127(11):1502- 1508.
14. Ganetsky A, Shah A, Miano TA, et al. Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(4):568-572.
15. Devine SM, Owzar K, Blum W, et al. Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced- intensity conditioning regimen: results from cancer and leukemia group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. J Clin Oncol. 2015;33(35):4167-4175.
16. Socié G, Vigouroux S, Yakoub-Agha I, et al. A phase 3 randomized trial comparing ino- limomab vs usual care in steroid-resistant acute GVHD. Blood. 2017;129(5):643-649.
17. Armand P, Kim HT, Sainvil M-M, et al. The addition of sirolimus to the graft-versus-
host disease prophylaxis regimen in reduced intensity allogeneic stem cell trans- plantation for lymphoma: a multicentre randomized trial. Br J Haematol. 2016;173 (1):96-104.
18. Leisenring WM, Martin PJ, Petersdorf EW, et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood. 2006;108(2):749-755.
19. Bejanyan N, Rogosheske J, DeFor T, et al. Higher dose of mycophenolate mofetil reduces acute graft-versus-host disease in reduced-intensity conditioning double umbilical cord blood transplantation. Biol Blood Marrow Transplant. 2015;21(5):926- 933.
20. Bolaños-Meade J, Logan BR, Alousi AM, et al. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood. 2014;124(22):3221-3227.
21. Wakui M, Okamoto S, Ishida A, et al. Prospective evaluation for upper gastroin- testinal tract acute graft-versus-host disease after hematopoietic stem cell transplanta- tion. Bone Marrow Transplant. 1999;23(6):573-578.
22. Ross W, Ghosh S, Dekovich A, et al. Endoscopic biopsy diagnosis of acute gas- trointestinal graft-versus-host disease: rec- tosigmoid biopsies are more sensitive than upper gastrointestinal biopsies. Am J Gastroenterol. 2008;103(4):982-989.
23. Kreisel W, Dahlberg M, Bertz H, et al. Endoscopic diagnosis of acute intestinal GVHD following allogeneic hematopoietic SCT: a retrospective analysis in 175 patients. Bone Marrow Transplant. 2012;47(3):430-438.
24. Aslanian H, Chander B, Robert M, et al. Prospective evaluation of acute graft-ver- sus-host disease. Dig Dis Sci. 2011; 57(3):720-725.
25. Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010;363(22):2091-2101.
26. Weisdorf D, Spellman S, Haagenson M, et al. Classification of HLA-matching for ret- rospective analysis of unrelated donor transplantation: revised definitions to pre- dict survival. Biol Blood Marrow Transplant. 2008;14(7):748-758.
27. Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regi- mens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628- 1633.
28. Lee SJ, Klein JP, Barrett AJ, et al. Severity of chronic graft-versus-host disease: associa- tion with treatment-related mortality and relapse. Blood. 2002;100(2):406-414.
29. Kaplan EL, Meier P. Nonparametric estima- tion from incomplete observations. J Amer Statist Assn. 1958;53:457-481.
30. Hamilton BK, Rybicki L, Dean R, et al. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplanta- tion. Am J Hematol. 2015;90(2):144-148.
31. Cutler C, Logan B, Nakamura R, et al. Tacrolimus/sirolimus vs tacrolimus/methotrexate as GVHD pro- phylaxis after matched, related donor allo- geneic HCT. Blood. 2014;124(8):1372-1377.
32. Kharfan-Dabaja M, Mhaskar R, Reljic T, et al. Mycophenolate mofetil versus methotrexate for prevention of graft-ver- sus-host disease in people receiving allo- geneic hematopoietic stem cell transplanta- tion. Cochrane Database Syst Rev. 2014; 25(7):CD010280.
33. MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: Comparison of grading systems. Biol Blood Marrow Transplant. 2002; 8(7):387-394.
34. Abraham J, Janin A, Gornet J-M, et al. Clinical severity scores in gastrointestinal graft-versus-host disease. Transplantation. 2014;97(9):965-971.
35. Ip S, Marquez V, Schaeffer DF, Donnellan F. Sensitivities of biopsy sites in the endo- scopic evaluation of graft-versus-host dis- ease: retrospective review from a tertiary center. Dig Dis Sci. 2016;61(8):2351-2356.
36. Thompson B, Salzman D, Steinhauer J, Lazenby AJ, Wilcox CM. Prospective endo- scopic evaluation for gastrointestinal graft- versus-host disease: determination of the best diagnostic approach. Bone Marrow Transplant. 2006;38(5):371-376.
37. Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host disease: grade and outcome in patients with chronic myeloge- nous leukemia. Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Blood. 1995; 86(2):813-818.
38. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487-1496.
39. MacMillan ML, DeFor TE, Weisdorf DJ. What predicts high risk acute graft-versus- host disease (GVHD) at onset?: identifica- tion of those at highest risk by a novel acute GVHD risk score. Br J Haematol. 2012;157(6):732-741.
40. Mehta RS, Cao Q, Holtan S, MacMillan ML, Weisdorf DJ. Upper GI GVHD: similar outcomes to other grade II graft-versus- host disease. Bone Marrow Transplant. 2017;52(8):1180-1186.
haematologica | 2018; 103(10)
1719